Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generics Bulletin Originals

Set Alert for Originals
What's Next?

What’s Next? Five Things To Look Out For In March

Prepare for all the biggest industry actions and events in March 2023 with Generics Bulletin’s monthly column.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In February

February brings a potentially sizeable launch in the US, multiple court cases in both the US and Europe and a gala generics and biosimilars event stretching across four days in Florida.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In January

The biggest loss of exclusivity in pharmaceutical history is set to steal headlines in the first month of 2023, as Teva begins a new year with a new CEO.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In December

In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.

Biosimilars Generic Drugs
See All

‘In A Word, Complicated’ – AAM’s Burton Talks US Biosimilars

With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is “doing better, but we still have improvements to make.”

Biosimilars United States

Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics

With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks to Generics Bulletin about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.

Generic Drugs Regulation

IGBA Seeks To Underline Value And Access

Speaking with Generics Bulletin at the IGBA’s annual conference in February, chair Jonathan Kimball explained how the association is conveying the value of generics and biosimilars to international industry stakeholders.

Generic Drugs Biosimilars

AAM’s Baeder Takes A Focused Approach To Articulating Industry Priorities

Christine Baeder, Teva’s chief operating officer for US generics and biosimilars, was named chair of the AAM’s board in February. Speaking with Generics Bulletin, she sets out her priorities against the backdrop of a US generics industry that is now at an “inflection point” for sustainability.

Leadership United States
See All
Pricewatch UK

Wholesaler Hike Drives UK Price Spike In February

Increases by one particular wholesaler led to steep rises for a number of UK generics in February, according to market researcher WaveData.

Market Intelligence Generic Drugs

UK Penicillin Prices Spike In January

Our Pricewatch UK feature has seen a first with WaveData’s figures for January 2023, as all nine of our top Biggest Risers belonged to the same group of medicines, penicillins.

Market Intelligence Pricing Strategies

UK Prices Double For Multiple Molecules In December

Average trade prices for multiple products more than doubled in December in the UK, according to the latest figures from market researcher WaveData.

Market Intelligence Pricing Strategies

UK Prices See A Raft Of Rises In November

Multiple treble-digit price rises were seen for UK generics in November as a lengthy list of price concessions was issued by the Department of Health and Social Care.

Market Intelligence Pricing Strategies
See All